Portfolio Holdings Detail for ISIN IE00BMWPV470
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist)
Issuer Blackrock

ETF Ticker SUAP(GBP) LSE
ETF Ticker SUAP.LS(GBP) CXE
ETF Ticker SUAP.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028: (RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win: Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer: Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-11-11 (Tuesday)	37,128	USD 16,780,000	USD 16,780,000	0	USD 380,562	USD 451.95	USD 441.7
2025-11-10 (Monday)	37,128	USD 16,399,438	USD 16,399,438	-54	USD -61,033	USD 441.7	USD 442.7
2025-11-07 (Friday)	37,182	USD 16,460,471	USD 16,460,471	-27	USD 70,279	USD 442.7	USD 440.49
2025-11-06 (Thursday)	37,209	USD 16,390,192	USD 16,390,192	0	USD 220,649	USD 440.49	USD 434.56
2025-11-05 (Wednesday)	37,209	USD 16,169,543	USD 16,169,543	-54	USD 389,780	USD 434.56	USD 423.47
2025-11-04 (Tuesday)	37,263	USD 15,779,763	USD 15,779,763	0	USD -394,987	USD 423.47	USD 434.07
2025-11-03 (Monday)	37,263	USD 16,174,750	USD 16,174,750	0	USD -818,669	USD 434.07	USD 456.04
2025-10-31 (Friday)	37,263	USD 16,993,419	USD 16,993,419	0	USD 241,465	USD 456.04	USD 449.56
2025-10-30 (Thursday)	37,263	USD 16,751,954	USD 16,751,954	0	USD -1,193,534	USD 449.56	USD 481.59
2025-10-29 (Wednesday)	37,263	USD 17,945,488	USD 17,945,488	-189	USD 121,707	USD 481.59	USD 475.91
2025-10-28 (Tuesday)	37,452	USD 17,823,781	USD 17,823,781	0	USD -99,997	USD 475.91	USD 478.58
2025-10-27 (Monday)	37,452	USD 17,923,778	USD 17,923,778	0	USD 567,398	USD 478.58	USD 463.43

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BMWPV470

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 SELL -54 449.680 440.930 441.805 USD -23,857 400.24 Loss of -2,245 on sale
2025-11-07 SELL -27 443.587 430.835 432.110 USD -11,667 399.60 Loss of -878 on sale
2025-11-05 SELL -54 438.530 417.000 419.153 USD -22,634 398.44 Loss of -1,119 on sale
2025-10-29 SELL -189 481.590 482.730 482.616 USD -91,214 394.23 Loss of -16,705 on sale
2025-10-23 SELL -54 464.000 468.860 468.374 USD -25,292 388.78 Loss of -4,298 on sale
2025-10-21 SELL -54 474.000 490.050 488.445 USD -26,376 385.79 Loss of -5,543 on sale
2025-10-16 SELL -27 481.070 488.390 487.658 USD -13,167 379.98 Loss of -2,907 on sale
2025-10-14 SELL -108 469.360 479.690 478.657 USD -51,695 376.31 Loss of -11,053 on sale
2025-10-07 SELL -54 459.580 462.630 462.325 USD -24,966 374.58 Loss of -4,738 on sale
2025-09-26 SELL -54 446.400 453.050 452.385 USD -24,429 360.97 Loss of -4,936 on sale
2025-09-24 SELL -57 458.370 462.690 462.258 USD -26,349 356.20 Loss of -6,045 on sale
2025-09-18 SELL -54 452.170 456.940 456.463 USD -24,649 353.68 Loss of -5,550 on sale
2025-09-10 BUY 52 469.310 480.050 478.976 USD 24,907 333.18
2025-08-21 SELL -108 467.550 467.710 467.694 USD -50,511 319.23 Loss of -16,034 on sale
2025-08-20 SELL -135 458.310 466.310 465.510 USD -62,844 314.27 Loss of -20,418 on sale
2025-07-10 BUY 162 322.640 324.820 324.602 USD 52,586 313.96
2025-07-09 SELL -135 320.870 322.680 322.499 USD -43,537 313.69 Loss of -1,189 on sale
2025-07-08 SELL -736 317.500 328.990 327.841 USD -241,291 313.54 Loss of -10,526 on sale
2025-06-27 SELL -351 322.830 323.200 323.163 USD -113,430 309.04 Loss of -4,956 on sale
2025-06-26 SELL -27 318.250 325.000 324.325 USD -8,757 308.53 Loss of -426 on sale
2025-06-24 SELL -73 325.000 326.030 325.927 USD -23,793 306.67 Loss of -1,406 on sale
2025-06-20 SELL -552 309.700 314.500 314.020 USD -173,339 305.99 Loss of -4,434 on sale
2025-06-17 SELL -1,160 308.710 309.060 309.025 USD -358,469 304.59 Loss of -5,146 on sale
2025-06-13 SELL -135 307.990 308.020 308.017 USD -41,582 303.75 Loss of -577 on sale
2025-06-12 BUY 130 304.670 307.480 307.199 USD 39,936 303.63
2025-06-09 SELL -297 304.000 306.170 305.953 USD -90,868 304.80 Loss of -342 on sale
2025-06-06 SELL -78 300.830 310.220 309.281 USD -24,124 305.79 Loss of -272 on sale
2025-06-04 SELL -513 305.310 308.930 308.568 USD -158,295 304.93 Loss of -1,866 on sale
2025-06-03 SELL -135 303.770 307.850 307.442 USD -41,505 306.09 Loss of -183 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	SELL	-54	449.680	440.930	441.805	USD -23,857	400.24 Loss of -2,245 on sale
2025-11-07	SELL	-27	443.587	430.835	432.110	USD -11,667	399.60 Loss of -878 on sale
2025-11-05	SELL	-54	438.530	417.000	419.153	USD -22,634	398.44 Loss of -1,119 on sale
2025-10-29	SELL	-189	481.590	482.730	482.616	USD -91,214	394.23 Loss of -16,705 on sale
2025-10-23	SELL	-54	464.000	468.860	468.374	USD -25,292	388.78 Loss of -4,298 on sale
2025-10-21	SELL	-54	474.000	490.050	488.445	USD -26,376	385.79 Loss of -5,543 on sale
2025-10-16	SELL	-27	481.070	488.390	487.658	USD -13,167	379.98 Loss of -2,907 on sale
2025-10-14	SELL	-108	469.360	479.690	478.657	USD -51,695	376.31 Loss of -11,053 on sale
2025-10-07	SELL	-54	459.580	462.630	462.325	USD -24,966	374.58 Loss of -4,738 on sale
2025-09-26	SELL	-54	446.400	453.050	452.385	USD -24,429	360.97 Loss of -4,936 on sale
2025-09-24	SELL	-57	458.370	462.690	462.258	USD -26,349	356.20 Loss of -6,045 on sale
2025-09-18	SELL	-54	452.170	456.940	456.463	USD -24,649	353.68 Loss of -5,550 on sale
2025-09-10	BUY	52	469.310	480.050	478.976	USD 24,907	333.18
2025-08-21	SELL	-108	467.550	467.710	467.694	USD -50,511	319.23 Loss of -16,034 on sale
2025-08-20	SELL	-135	458.310	466.310	465.510	USD -62,844	314.27 Loss of -20,418 on sale
2025-07-10	BUY	162	322.640	324.820	324.602	USD 52,586	313.96
2025-07-09	SELL	-135	320.870	322.680	322.499	USD -43,537	313.69 Loss of -1,189 on sale
2025-07-08	SELL	-736	317.500	328.990	327.841	USD -241,291	313.54 Loss of -10,526 on sale
2025-06-27	SELL	-351	322.830	323.200	323.163	USD -113,430	309.04 Loss of -4,956 on sale
2025-06-26	SELL	-27	318.250	325.000	324.325	USD -8,757	308.53 Loss of -426 on sale
2025-06-24	SELL	-73	325.000	326.030	325.927	USD -23,793	306.67 Loss of -1,406 on sale
2025-06-20	SELL	-552	309.700	314.500	314.020	USD -173,339	305.99 Loss of -4,434 on sale
2025-06-17	SELL	-1,160	308.710	309.060	309.025	USD -358,469	304.59 Loss of -5,146 on sale
2025-06-13	SELL	-135	307.990	308.020	308.017	USD -41,582	303.75 Loss of -577 on sale
2025-06-12	BUY	130	304.670	307.480	307.199	USD 39,936	303.63
2025-06-09	SELL	-297	304.000	306.170	305.953	USD -90,868	304.80 Loss of -342 on sale
2025-06-06	SELL	-78	300.830	310.220	309.281	USD -24,124	305.79 Loss of -272 on sale
2025-06-04	SELL	-513	305.310	308.930	308.568	USD -158,295	304.93 Loss of -1,866 on sale
2025-06-03	SELL	-135	303.770	307.850	307.442	USD -41,505	306.09 Loss of -183 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	216,727	3,259	396,243	54.7%
2025-09-18	172,875	397	386,432	44.7%
2025-09-17	246,547	167	472,292	52.2%
2025-09-16	88,846	60	226,336	39.3%
2025-09-15	148,258	13,572	435,689	34.0%
2025-09-12	134,122	300	244,968	54.8%
2025-09-11	219,868	7,820	411,702	53.4%
2025-09-10	543,326	7,595	916,898	59.3%
2025-09-09	705,540	33,731	1,550,899	45.5%
2025-09-08	175,158	440	388,715	45.1%
2025-09-05	127,116	335	311,252	40.8%
2025-09-04	110,930	2,555	236,568	46.9%
2025-09-03	182,386	8,982	562,921	32.4%
2025-09-02	132,770	14,416	358,476	37.0%
2025-08-29	93,216	2,181	276,594	33.7%
2025-08-28	60,182	1,254	226,865	26.5%
2025-08-27	277,667	1,084	440,577	63.0%
2025-08-26	243,404	919	447,421	54.4%
2025-08-25	156,551	15,662	374,276	41.8%
2025-08-22	228,596	1,309	408,152	56.0%
2025-08-21	123,996	2,862	248,300	49.9%
2025-08-20	149,638	13,723	316,983	47.2%
2025-08-19	144,320	1,143	308,399	46.8%
2025-08-18	371,318	34,264	525,786	70.6%
2025-08-15	104,018	13,245	265,620	39.2%
2025-08-14	133,272	4,443	505,528	26.4%
2025-08-13	183,271	1,390	1,017,623	18.0%
2025-08-12	173,045	4,046	693,018	25.0%
2025-08-11	239,199	7,600	451,248	53.0%
2025-08-08	168,755	3,199	466,744	36.2%
2025-08-07	308,810	4,452	527,399	58.6%
2025-08-06	202,151	12,590	548,349	36.9%
2025-08-05	256,295	13,237	826,283	31.0%
2025-08-04	411,114	36,303	729,949	56.3%
2025-08-01	350,060	60,108	764,943	45.8%
2025-07-31	829,191	6,023	1,541,015	53.8%
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist)
Issuer	Blackrock
ETF Ticker	SUAP(GBP) LSE
ETF Ticker	SUAP.LS(GBP) CXE
ETF Ticker	SUAP.L(GBP) LSE